Tech Company Financing Transactions
RedShift BioAnalytics Funding Round
RedShift BioAnalytics closed a $18 million Series D financing round on 1/31/2020. Backers included Waters Corporation.
Transaction Overview
Company Name
Announced On
1/31/2020
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series D
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
131 Middlesex Turnpike
Burlington, MA 01803
USA
Burlington, MA 01803
USA
Phone
Website
Email Address
Overview
RedShiftBio is a provider of innovative analytical instrumentation for the research, development and manufacture of protein therapeutic drugs. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS) that enables direct probing of the biophysical structure of proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Julien Bradley
Chief Operating Officer
Chip Marshall
Chief Technical Officer
Eugene Ma
VP - Bus. Development
Jeffrey Zonderman
VP - Engineering
Richard Sharp
Browse more venture capital transactions:
Prev: 1/31/2020: Vizgen venture capital transaction
Next: 2/3/2020: NGD Systems venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs